While Medicare doesn't cover these types of drugs, beneficiaries enrolled in Medicare Advantage plans might have the medications covered
If shedding fat is the goal, certain fat loss peptides have more direct research behind them than NAD+ does
Whether treatment is medically appropriate in an individual case must always be assessed individually
These drug supply issues are a great opportunity to have patient management reviews, emphasise principles around healthy lifestyle, and review therapies including prescribing options or even de-prescribing if possible. Alternative treatment options suggested by the RACGP include: Liraglutide, which is administered once daily and has evidence of cardiovascular benefit, but is not subsidised by PBS SGLT-2 inhibitors, especially in those who also have cardiovascular disease, multiple cardiovascular risk factors and/or kidney disease DPP-4 inhibitors, which may be useful in those who do not have cardiovascular disease, multiple cardiovascular risk factors or kidney disease, and are unable to achieve optimal blood glucose levels Sulphonylureas or insulin (initiation or titrated doses), but these may lead to risks for hypoglycaemia and weight gain The twice daily exenatide (Byetta) is not recommended as a potential substitute, as it has been discontinued and is also no longer available
